Products
Rimexolone was commercially available in the form of eye drops (Vexol). It had been approved in many countries since 1997.
Structure and properties
Rimexolone (C24H34O3, Mr = 370.5 g/mol) exists as a white powder that is insoluble in water. Because of its poor solubility in water, it is formulated as a suspension in drugs.
Effects
Rimexolone (ATC S01BA13) has anti-inflammatory, antipruritic, and antiallergic properties.
Indications
For the treatment of inflammation following ocular surgical procedures, anterior uveitis, and other inflammatory noninfectious ocular conditions.
Dosage
According to the SmPC. The drug is in suspension form, and the vial must therefore be shaken well before use. See also under Administering eye drops. The dose depends on the indication and is usually 1-2 drops per affected eye 4 times daily. Discontinuation should be gradual.
Contraindications
Rimexolone is contraindicated in hypersensitivity and certain local infections. For complete precautions, see the drug label.
Interactions
Drug-drug interactions have not been reported. Other ophthalmic agents should be administered at least 15 minutes apart.
Adverse effects
The most common possible adverse effects include blurred vision, increased intraocular pressure, discharge, an uncomfortable feeling, eye pain, and foreign body sensation.